Legend Biotech (LEGN) Cost of Revenue (2022 - 2026)

Legend Biotech (LEGN) has 5 years of Cost of Revenue data on file, last reported at $175.4 million in Q1 2026.

• Quarterly Cost of Revenue rose 152.37% year-over-year to $175.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $453.0 million (up 91.34% YoY) and the FY2024 annual result came in at $216.4 million, up 50.03% from the prior year.
• Cost of Revenue grew to $175.4 million in Q1 2026, from $113.3 million in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $175.4 million in Q1 2026 to a low of $23.0 million in Q4 2022.
• A 5-year average of $61.6 million and a median of $47.2 million in 2024 frame the typical range for Cost of Revenue.
• Annual changes were most pronounced in 2024 — Cost of Revenue grew 20.77% — and 2026, when it jumped 152.37%.
• Tracing LEGN's Cost of Revenue over 5 years: stood at $23.0 million in 2022, then surged by 41.31% to $32.4 million in 2023, then soared by 113.86% to $69.4 million in 2024, then soared by 63.21% to $113.3 million in 2025, then jumped by 54.86% to $175.4 million in 2026.
• The last three Cost of Revenue figures came in at $175.4 million (Q1 2026), $113.3 million (Q3 2025), and $94.9 million (Q2 2025), per Business Quant data.